Acquisition Opportunity Lucid Labs was acquired by Velosity on September 15, 2026, creating an integrated medtech platform that spans product design, engineering, and precision manufacturing. This presents a potential cross-sell opportunity for Velosity to expand into Lucid’s existing client base and for Lucid’s capabilities to augment Velosity’s manufacturing footprint.

Integrated Services Lucid Labs offers end-to-end support from concept through production, including rapid prototyping, FEA, PCB design, and multiple manufacturing processes. This full-spectrum capability aligns with medtech customers seeking a single partner to reduce time to market and coordinate cross-disciplinary development.

Mid-market Focus With a team size of 11-50 and a revenue range of one to ten million, Lucid Labs operates in the mid-market for medical device development, a segment that often requires flexible engagement models and scalable teams, signaling suitability for contract work, program-based engagements, or dedicated development teams.

Tech-Driven Differentiator Strong proficiency in mechanical and electrical product design, rapid prototyping, and simulation (FEA) using SolidWorks, Creo, Altium, and other tools positions Lucid Labs to pitch faster development cycles and validated concepts to inventors, startups, and Fortune 500 R&D teams.

Growth Signals Recent news indicates strategic consolidation in medtech design and manufacturing ecosystems, suggesting increased demand for integrated design-to-manufacture partners. This environment creates opportunities to offer end-to-end workflows, process development, and scalable manufacturing services to both new and existing clients.